Combination of PD-1 Monoclonal Antibody and HPV Vaccine in Patients With Cervical Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04096911|
Recruitment Status : Unknown
Verified September 2019 by Buhai Wang, Northern Jiangsu Province People's Hospital.
Recruitment status was: Recruiting
First Posted : September 20, 2019
Last Update Posted : September 20, 2019
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Uterine Cervical Neoplasms Cervical Cancer Cervical Neoplasms Cervix Cancer||Drug: Sintilimab Drug: quadrivalent HPV vaccine||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||20 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Single-arm, Single-center, Phase II Clinical Study Evaluating Efficacy of PD-1 Monoclonal Antibody Combined With HPV Vaccine in the Patients With Cervical Cancer（CC）Who Fails in or Can Not Endure the Standard Treatment|
|Actual Study Start Date :||July 31, 2019|
|Estimated Primary Completion Date :||March 31, 2021|
|Estimated Study Completion Date :||March 31, 2021|
Experimental: Sintilimab and HPV Vaccine
Sintilimab 200 mg intravenously every 3 weeks ，3 doses of quadrivalent HPV vaccine intramuscularly at day 1,60,180
Sintilimab 200 mg intravenously every 3 weeks
Other Name: IBI308
Drug: quadrivalent HPV vaccine
The first dose of quadrivalent HPV vaccine intramuscularly at the day before the first dose of Sintilimab ，the second and third doses of quadrivalent HPV vaccine intramuscularly at the 60th and 180th days respectively
Other Name: Gardasil 4
- Objective Response Rate [ Time Frame: 24 months ]complete response plus partial response as determined by RECIST 1.1
- Progression-free survival [ Time Frame: Time from study entry to time of progression or death, whichever occurs first, assessed up to 42 months ]Kaplan-Meier median estimates and curves will be used to describe PFS survival functions
- Overall survival [ Time Frame: Time from study entry to time of death or the date of last contact, assessed up to 42 months ]Kaplan-Meier median estimates and curves will be used to describe OS survival functions
- Duration of Response [ Time Frame: Time from the first evaluation of the tumor is CR or PR to the first evaluation is PD or death, assessed up to 42 months ]Kaplan-Meier median estimates and curves will be used to describe DOR survival functions
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||Female|
|Accepts Healthy Volunteers:||No|
- Patients must have persistent, recurrent or metastatic squamous cell carcinoma, adenosquamous carcinoma or adenocarcinoma of the cervix with documented disease progression (disease not amendable to curative therapy)
- All patents must have measurable disease as defined by RECIST 1.1; measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded); each lesion must be >= 10 mm when measured by computed tomography (CT), magnetic resonance imaging (MRI) or caliper measurement by clinical exam;lymph nodes must be >= 15 mm in short axis when measured by CT or MRI
- Patients must have at least one "target" lesion" to be used to assess response on this protocol as defined by RECIST 1.1; tumors within a previously irradiated field will be designated as "non-target" lesions unless progression is documented or a biopsy is obtained to confirm persistence at least 90 days following completion of radiation therapy
- In the state of HPV infection
Appropriate for study entry based on the following diagnostic workup:
- History/physical examination within 28 days prior to registration
- Imaging of target lesion(s) within 28 days prior to registration
Further protocol-specific assessments:
- Recovery from adverse effects of recent surgery, radiotherapy or chemotherapy
- Any other prior therapy directed at the malignant tumor including chemotherapy, biologic/targeted agents and immunologic agents must be discontinued at least three weeks prior to registration Investigation agents must be discontinued for at least 30 days prior to registration
- Any prior radiation therapy must be completed at least 4 weeks prior to registration
- At least 4 weeks must have elapsed since any major surgery prior to registration
- Patients must have had one prior systemic chemotherapeutic regimen for management of persistent, recurrent or metastatic carcinoma of the cervix (e.g.; paclitaxel/cisplatin, paclitaxel/cisplatin/bevacizumab); chemotherapy administered concurrent with primary radiation (e.g.; weekly cisplatin) is not counted as a systemic chemotherapy regimen; adjuvant chemotherapy given following the completion of radiation therapy (or concurrent chemotherapy and radiation therapy) is not counted as a systemic chemotherapy regimen (e.g.; paclitaxel and carboplatin for up to 4 cycles); NOTE: patients who have received more than one prior regimen are NOT eligible
- Have a performance status of 0 or 1 on the ECOG Performance Scale
- Absolute neutrophil count (ANC) >= 1,500/ul
- Platelets >= 100,000/ul
- Creatinine =< 1.5 x institutional upper limit of normal (ULN) or creatinine clearance (CrCl) >= 40 mL/min using Cockcroft-Gault formula
- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN
- Has disease which is amenable to radical treatment with surgery or radiation or a combination of treatments.
- Is currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of treatment.
- Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment.
- Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1 or who has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to a previously administered agent.
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1 or who has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to a previously administered agent.
- Note: Subjects with ≤ Grade 2 neuropathy are an exception to this criterion and may qualify for the study.
- Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy.
- Has a known additional malignancy that is progressing or requires active treatment.
- Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Subjects with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging for at least four weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 7 days prior to trial treatment.
- Has an active autoimmune disease requiring systemic treatment within the past 3 months or a documented history of clinically severe autoimmune disease, or a syndrome that requires systemic steroids or immunosuppressive agents. Subjects with vitiligo or resolved childhood asthma/atopy would be an exception to this rule. Subjects that require intermittent use of bronchodilators or local steroid injections would not be excluded from the study. Subjects with hypothyroidism stable on hormone replacement or Sjorgen's syndrome will not be excluded from the study.
- Has an active infection requiring systemic therapy.
- Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.
- Has known hypersensitivity to Sintilimab or its formulation
- Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
- Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment.
- Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways).
- Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).
- Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA [qualitative] is detected).
- History of serotonergic syndrome.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04096911
|Contact: Buhai Wangfirstname.lastname@example.org|
|Contact: Yuechao Wuemail@example.com|
|People's hospital of northern jiangsu||Recruiting|
|Yangzhou, Jiangsu, China, 225000|
|Contact: Buhai Wang, MD/PhD 18051062288 firstname.lastname@example.org|
|Contact: Yuechao Wu, master 18762313298 email@example.com|
|Principal Investigator: Buhai Wang, MD/PhD|
|Principal Investigator: Yuechao Wu, master|
|Sub-Investigator: Liqin Liu, master|
|Sub-Investigator: Yichen Liang, MD|
|Sub-Investigator: Yinxia Wu, MD|
|Principal Investigator: Yuxiang Huang, PhD|
|Sub-Investigator: Feng Han, master|
|Sub-Investigator: Xiaosong Ma, master|
|Study Chair:||Buhai Wang||People's hospital of northern jiangsu|
|Study Director:||Yuechao Wu||People's hospital of northern jiangsu|
Publications of Results:
|Responsible Party:||Buhai Wang, doctor, Northern Jiangsu Province People's Hospital|
|Other Study ID Numbers:||
|First Posted:||September 20, 2019 Key Record Dates|
|Last Update Posted:||September 20, 2019|
|Last Verified:||September 2019|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|
PD-1 Monoclonal Antibody
Uterine Cervical Neoplasms
Genital Neoplasms, Female
Neoplasms by Site
Uterine Cervical Diseases